Anixa Biosciences, Inc.
ANIX · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $2 | $0 |
| % Growth | -100% | -100% | 481,656.1% | – |
| Gross Profit | -$0 | $0 | $2 | $0 |
| % Margin | – | 23.3% | 100% | 24.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -5,221.4% | -0.6% | -2,552.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -4,671.9% | -0.5% | -2,526.2% |
| EPS Diluted | -0.39 | -0.32 | -0.44 | -0.45 |
| % Growth | -21.9% | 27.3% | 2.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |